Novartis (NVS) Stock Forecast & Price Target

$97.33 -1.06 (-1.08%)

(As of 05:27 PM ET)

Novartis - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Reduce

Based on 9 Analyst Ratings

Sell
2

Hold
7

Buy
0

Based on 9 Wall Street analysts who have issued ratings for Novartis in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 9 analysts, 2 have given a sell rating, and 7 have given a hold rating for NVS.

Consensus Price Target

$121.50
24.83% Upside

According to the 9 analysts' twelve-month price targets for Novartis, the average price target is $121.50. The highest price target for NVS is $130.00, while the lowest price target for NVS is $114.00. The average price target represents a forecasted upside of 24.83% from the current price of $97.33.

Get the Latest News and Ratings for NVS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Novartis and its competitors.

NVS Analyst Ratings Over Time

Type	Current Forecast 12/31/23 to 12/30/24	1 Month Ago 12/1/23 to 11/30/24	3 Months Ago 10/2/23 to 10/1/24	1 Year Ago 12/31/22 to 12/31/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	0 Buy rating(s)	0 Buy rating(s)	0 Buy rating(s)	1 Buy rating(s)
Hold	7 Hold rating(s)	8 Hold rating(s)	7 Hold rating(s)	4 Hold rating(s)
Sell	2 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$121.50	$121.50	$120.70	$85.00
Forecasted Upside	24.83% Upside	14.87% Upside	5.39% Upside	-15.82% Downside
Consensus Rating	Reduce	Reduce	Reduce	Hold

I was wrong. Dead wrong. (Ad)

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Here’s the full story for you.

NVS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

NVS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Novartis Stock vs. The Competition

Type	Novartis	Medical Companies	S&P 500
Consensus Rating Score	1.78	2.81	2.51
Consensus Rating	Reduce	Moderate Buy	Moderate Buy
Predicted Upside	24.56% Upside	23,902.24% Upside	15.04% Upside
News Sentiment Rating	Neutral News See Recent NVS News	Positive News	Neutral News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/4/2024	HSBC 3 of 5 stars		Downgrade	Hold ➝ Reduce
11/19/2024	Erste Group Bank 3 of 5 stars		Reiterated Rating	Buy ➝ Hold
10/30/2024	BMO Capital Markets 4 of 5 stars		Boost Target	Market Perform ➝ Market Perform	$118.00 ➝ $120.00	+8.53%
9/11/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$135.00 ➝ $130.00	+11.08%
9/5/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Quigley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$119.00 ➝ $121.00	+1.37%
9/3/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
7/19/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Hold
6/24/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Field Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
1/23/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Equal Weight	$114.00	+5.09%
4/19/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$75.00 ➝ $85.00	-13.28%
1/26/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral
1/3/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underweight ➝ Neutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 07:25 PM ET.

Should I Buy Novartis Stock? NVS Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, December 26, 2024. Please send any questions or comments about these Novartis pros and cons to contact@marketbeat.com.

Novartis
Bull Case

Here are some ways that investors could benefit from investing in Novartis AG:

Analysts have raised their FY2024 earnings per share estimates to $7.60, indicating a positive outlook for the company's profitability.
Novartis AG recently reported quarterly earnings of $2.06 per share, surpassing the consensus estimate of $1.94, which reflects strong operational performance.
The stock is currently trading at $97.77, which is below its 52-week high of $120.92, suggesting potential for price appreciation.
Institutional interest is growing, with Dorsey Wright & Associates acquiring a new position valued at approximately $2.37 million, indicating confidence from large investors.
The company maintains a strong net margin of 35.96% and a return on equity of 34.80%, showcasing effective management and profitability.

Novartis
Bear Case

Investors should be bearish about investing in Novartis AG for these reasons:

Several analysts have downgraded their ratings on Novartis AG, with HSBC and Jefferies Financial Group both reducing their ratings, which may indicate a lack of confidence in the stock's future performance.
The stock has a consensus rating of "Hold," suggesting that many analysts do not see significant upside potential in the near term.
Novartis AG's price target has been adjusted downwards by Bank of America from $135.00 to $130.00, reflecting a more cautious outlook.
Despite strong earnings, the stock has experienced volatility, trading down from its recent highs, which could be a concern for risk-averse investors.
Hedge funds and institutional investors only own 13.12% of the company's stock, which may indicate a lack of widespread institutional confidence in the stock.

NVS Forecast - Frequently Asked Questions

: According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Novartis is $121.50, with a high forecast of $130.00 and a low forecast of $114.00.
: 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 2 sell ratings and 7 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "reduce" NVS shares.
: According to analysts, Novartis's stock has a predicted upside of 24.83% based on their 12-month stock forecasts.
: Over the previous 90 days, Novartis's stock had 1 downgrade by analysts.
: Novartis has been rated by research analysts at BMO Capital Markets, Erste Group Bank, and HSBC in the past 90 days.
: Analysts like Novartis less than other "medical" companies. The consensus rating for Novartis is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how NVS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Kamala’s final humiliation (Ad)

The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware of… yet have the potential to deliver colossal returns over the next four years. I’m not talking about Tesla, Palantir, or anything else you’ve heard parroted by the mainstream financial press. No. These are Trump’s Secret Stocks.

It’s all waiting for you here.

This page (NYSE:NVS) was last updated on 12/30/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novartis (NVS) Stock Forecast & Price Target